GLP Semaglutide: the once-weekly medicine reshaping weight management in the UK

You've heard the term GLP-1 everywhere, here's what it actually means for semaglutide

Picture this: you finish a meal, and your gut releases a hormone called glucagon-like peptide 1 (GLP-1). It travels to your brain and signals that you've had enough; it slows the pace at which food leaves your stomach; it nudges your pancreas to release insulin at the right moment. In people living with obesity, this signalling system can be less effective than it should be.

Semaglutide is engineered to slot into the same receptor that natural GLP-1 uses, but it lasts far longer in the body, long enough for a once-weekly injection or a daily tablet to keep the signal going consistently. The result, for many people, is a genuine reduction in hunger and an easier relationship with portion sizes. It doesn't override your will; it adjusts the biological backdrop against which you make choices about food.

This is why the term GLP semaglutide has become such a common search, people trying to work out whether semaglutide is itself a GLP-1, or merely related to one. The short answer: semaglutide is a GLP-1 receptor agonist. The receptor is the target; semaglutide is the key. If you want to go deeper into that pharmacology, our guide to semaglutide as a GLP-1 receptor agonist unpacks the relationship between the two, and our explainer on semaglutide as a GLP-1 drug covers it in full.

The NHS medicines page for semaglutide is a reliable starting point for patient-level information on how the medicine works and what to watch for.

The Wegovy licence, the Ozempic confusion, and why the distinction matters

Both Wegovy and Ozempic contain semaglutide. That single fact produces enormous confusion online, and it matters practically.

Wegovy is licensed in the UK for weight management. Ozempic is licensed for type 2 diabetes. The dosing schedules are different, the licensed indications are different, and a prescriber writing for one cannot simply substitute the other. The MHRA is clear on this point, and so is the page we've written specifically on Wegovy's GLP-1 status if you want the regulatory detail spelled out.

There is also now a third semaglutide product to be aware of: Wegovy tablets, approved by the MHRA on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet schedule runs from 1.5 mg up to a 25 mg maintenance dose, taken first thing in the morning before food or drink. No refrigeration needed, which, for anyone who travels regularly or simply finds the injection daunting, changes the practical picture considerably.

Rybelsus, by contrast, is also an oral semaglutide product but licensed only for type 2 diabetes at its 3 mg, 7 mg and 14 mg strengths. Those are not steps on the Wegovy tablet ladder; they are a separate product for a separate indication.

You can read a fuller overview of the injection and tablet options on our Wegovy page, or explore the broader landscape of weight-loss treatments we work with.

What the clinical evidence actually shows, and what it doesn't guarantee

The STEP 1 trial is the pivotal study behind Wegovy's licence. It ran for 68 weeks, enrolled adults with obesity or overweight plus at least one weight-related condition, and found an average body-weight reduction of around 15% among participants taking semaglutide 2.4 mg weekly alongside lifestyle changes. That figure comes from the published trial paper in the New England Journal of Medicine and is cited in NICE's own appraisal of Wegovy.

Average figures carry a caveat worth stating plainly: they sit in the middle of a wide spread. Some participants lost considerably more; others considerably less. A clinical trial is not a personal prediction. Side effects also vary, the most commonly reported are gastrointestinal: nausea, loose stools, constipation, indigestion. For most people these are most noticeable in the early weeks of treatment or after a dose increase, and they tend to ease as the body adjusts. Staying well hydrated helps.

One question our prescribers hear fairly often: does semaglutide interact with penicillin or other antibiotics? Semaglutide slows gastric emptying, which in theory could affect oral medicines taken at the same time. Our page on semaglutide and penicillin addresses that specifically. For any personal medication review, your prescriber is the right person, not a search result.

If you are considering treatment and want to understand how a private prescription service works in practice, our semaglutide overview sets out the full picture, including cost context. Payday timing, holiday travel, Monday orders for next-day delivery, these practical questions come up a lot, and the consultation process is the right place to work through them with a clinician rather than guess.

NHS access versus a private prescription: what's realistic in 2025–26

NICE recommended semaglutide (Wegovy) for NHS use in its guidance TA875, but with a specific condition: it should be used for a maximum of two years, within a specialist weight management service that includes multidisciplinary support. NHS waiting lists for those services have been long in many areas, and the criteria are stricter than the private-prescription licence.

For people who do not meet NHS thresholds, or who do not want to wait, a regulated private pharmacy offering a clinician-reviewed prescription is the legal alternative. The process at a GPhC-registered service like ours starts with a consultation, reviewed the same day by a real prescriber, not automated software. Identity and weight are verified before any prescription is issued; a GP is notified in line with GPhC guidance.

If you have questions about how our clinical team approaches these assessments, the clinical team profile gives you a sense of who is reviewing your case. For general questions before you start, the FAQs page covers the most common ones.

Semaglutide as a GLP-1 medicine is among the most studied weight-management treatments in recent decades. Understanding what it does, what the evidence shows, and what the realistic options are puts you in a much better position to have a useful conversation with a prescriber. When you're ready for that conversation, speak to our prescribers through a free consultation.